CRL vs MDXG · rev $2.00B vs P/E 18, rev $123.4M
Charles River Laboratories (CRL) versus MiMedx Group Inc (MDXG) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
MiMedx Group Inc (MDXG) is a biotechnology company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported MDXG revenue for 2026-06-30 was $123.4M. Net income was -$25.7M. MDXG currently screens at market cap $537.7M and trailing P/E 18.1.
CRL currently screens at market cap $7.78B. MDXG currently screens at market cap $537.7M and trailing P/E 18.1.
Not investment advice. Open the CRL and MDXG stock pages for the full models.
Not investment advice.